These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

522 related articles for article (PubMed ID: 23293303)

  • 1. Clinical course and predictive value of congestion during hospitalization in patients admitted for worsening signs and symptoms of heart failure with reduced ejection fraction: findings from the EVEREST trial.
    Ambrosy AP; Pang PS; Khan S; Konstam MA; Fonarow GC; Traver B; Maggioni AP; Cook T; Swedberg K; Burnett JC; Grinfeld L; Udelson JE; Zannad F; Gheorghiade M;
    Eur Heart J; 2013 Mar; 34(11):835-43. PubMed ID: 23293303
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical profile and prognostic value of low systolic blood pressure in patients hospitalized for heart failure with reduced ejection fraction: insights from the Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST) trial.
    Ambrosy AP; Vaduganathan M; Mentz RJ; Greene SJ; Subačius H; Konstam MA; Maggioni AP; Swedberg K; Gheorghiade M
    Am Heart J; 2013 Feb; 165(2):216-25. PubMed ID: 23351825
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changes in renal function during hospitalization and soon after discharge in patients admitted for worsening heart failure in the placebo group of the EVEREST trial.
    Blair JE; Pang PS; Schrier RW; Metra M; Traver B; Cook T; Campia U; Ambrosy A; Burnett JC; Grinfeld L; Maggioni AP; Swedberg K; Udelson JE; Zannad F; Konstam MA; Gheorghiade M;
    Eur Heart J; 2011 Oct; 32(20):2563-72. PubMed ID: 21785107
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical profile and prognostic significance of natriuretic peptide trajectory following hospitalization for worsening chronic heart failure: findings from the ASTRONAUT trial.
    Greene SJ; Maggioni AP; Fonarow GC; Solomon SD; Böhm M; Kandra A; Prescott MF; Reimund B; Hua TA; Lesogor A; Zannad F; Gheorghiade M;
    Eur J Heart Fail; 2015 Jan; 17(1):98-108. PubMed ID: 25597870
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of aliskiren on postdischarge mortality and heart failure readmissions among patients hospitalized for heart failure: the ASTRONAUT randomized trial.
    Gheorghiade M; Böhm M; Greene SJ; Fonarow GC; Lewis EF; Zannad F; Solomon SD; Baschiera F; Botha J; Hua TA; Gimpelewicz CR; Jaumont X; Lesogor A; Maggioni AP;
    JAMA; 2013 Mar; 309(11):1125-35. PubMed ID: 23478743
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical course and predictive value of liver function tests in patients hospitalized for worsening heart failure with reduced ejection fraction: an analysis of the EVEREST trial.
    Ambrosy AP; Vaduganathan M; Huffman MD; Khan S; Kwasny MJ; Fought AJ; Maggioni AP; Swedberg K; Konstam MA; Zannad F; Gheorghiade M;
    Eur J Heart Fail; 2012 Mar; 14(3):302-11. PubMed ID: 22357577
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The prognostic significance of heart rate in patients hospitalized for heart failure with reduced ejection fraction in sinus rhythm: insights from the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study With Tolvaptan) trial.
    Greene SJ; Vaduganathan M; Wilcox JE; Harinstein ME; Maggioni AP; Subacius H; Zannad F; Konstam MA; Chioncel O; Yancy CW; Swedberg K; Butler J; Bonow RO; Gheorghiade M;
    JACC Heart Fail; 2013 Dec; 1(6):488-96. PubMed ID: 24622000
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum aldosterone is associated with mortality and re-hospitalization in patients with reduced ejection fraction hospitalized for acute heart failure: analysis from the EVEREST trial.
    Girerd N; Pang PS; Swedberg K; Fought A; Kwasny MJ; Subacius H; Konstam MA; Maggioni A; Gheorghiade M; Zannad F;
    Eur J Heart Fail; 2013 Nov; 15(11):1228-35. PubMed ID: 23787720
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Atrial fibrillation or flutter on initial electrocardiogram is associated with worse outcomes in patients admitted for worsening heart failure with reduced ejection fraction: findings from the EVEREST Trial.
    Mentz RJ; Chung MJ; Gheorghiade M; Pang PS; Kwasny MJ; Ambrosy AP; Vaduganathan M; O'Connor CM; Swedberg K; Zannad F; Konstam MA; Maggioni AP
    Am Heart J; 2012 Dec; 164(6):884-92.e2. PubMed ID: 23194489
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gender does not affect postdischarge outcomes in patients hospitalized for worsening heart failure with reduced ejection fraction (from the Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan [EVEREST] Trial).
    Shah AN; Mentz RJ; Gheorghiade M; Kwasny MJ; Fought AJ; Zannad F; Swedberg K; Maggioni AP; Konstam MA
    Am J Cardiol; 2012 Dec; 110(12):1803-8. PubMed ID: 22999071
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relief and Recurrence of Congestion During and After Hospitalization for Acute Heart Failure: Insights From Diuretic Optimization Strategy Evaluation in Acute Decompensated Heart Failure (DOSE-AHF) and Cardiorenal Rescue Study in Acute Decompensated Heart Failure (CARESS-HF).
    Lala A; McNulty SE; Mentz RJ; Dunlay SM; Vader JM; AbouEzzeddine OF; DeVore AD; Khazanie P; Redfield MM; Goldsmith SR; Bart BA; Anstrom KJ; Felker GM; Hernandez AF; Stevenson LW
    Circ Heart Fail; 2015 Jul; 8(4):741-8. PubMed ID: 26041600
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fatigue as a predictor of outcome in patients with heart failure: analysis of CORONA (Controlled Rosuvastatin Multinational Trial in Heart Failure).
    Perez-Moreno AC; Jhund PS; Macdonald MR; Petrie MC; Cleland JG; Böhm M; van Veldhuisen DJ; Gullestad L; Wikstrand J; Kjekshus J; Lewsey JD; McMurray JJ
    JACC Heart Fail; 2014 Apr; 2(2):187-97. PubMed ID: 24720928
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Haemoconcentration, renal function, and post-discharge outcomes among patients hospitalized for heart failure with reduced ejection fraction: insights from the EVEREST trial.
    Greene SJ; Gheorghiade M; Vaduganathan M; Ambrosy AP; Mentz RJ; Subacius H; Maggioni AP; Nodari S; Konstam MA; Butler J; Filippatos G;
    Eur J Heart Fail; 2013 Dec; 15(12):1401-11. PubMed ID: 23845795
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictive value of low relative lymphocyte count in patients hospitalized for heart failure with reduced ejection fraction: insights from the EVEREST trial.
    Vaduganathan M; Ambrosy AP; Greene SJ; Mentz RJ; Subacius HP; Maggioni AP; Swedberg K; Nodari S; Zannad F; Konstam MA; Butler J; Gheorghiade M;
    Circ Heart Fail; 2012 Nov; 5(6):750-8. PubMed ID: 23051949
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Changes in serum potassium levels during hospitalization in patients with worsening heart failure and reduced ejection fraction (from the EVEREST trial).
    Khan SS; Campia U; Chioncel O; Zannad F; Rossignol P; Maggioni AP; Swedberg K; Konstam MA; Senni M; Nodari S; Vaduganathan M; Subacius H; Butler J; Gheorghiade M;
    Am J Cardiol; 2015 Mar; 115(6):790-6. PubMed ID: 25728846
    [TBL] [Abstract][Full Text] [Related]  

  • 16. How often we need to measure brain natriuretic peptide (BNP) blood levels in patients admitted to the hospital for acute severe heart failure? Role of serial measurements to improve short-term prognostic stratification.
    Faggiano P; Valle R; Aspromonte N; D'Aloia A; Di Tano G; Barro S; Giovinazzo P; Milani L; Lorusso R; Dei Cas L
    Int J Cardiol; 2010 Apr; 140(1):88-94. PubMed ID: 19321212
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic significance of serum total cholesterol and triglyceride levels in patients hospitalized for heart failure with reduced ejection fraction (from the EVEREST Trial).
    Greene SJ; Vaduganathan M; Lupi L; Ambrosy AP; Mentz RJ; Konstam MA; Nodari S; Subacius HP; Fonarow GC; Bonow RO; Gheorghiade M;
    Am J Cardiol; 2013 Feb; 111(4):574-81. PubMed ID: 23206923
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic Value of the Severity of Clinical Congestion in Patients Hospitalized for Decompensated Heart Failure: Findings From the Japanese KCHF Registry.
    Aida K; Nagao K; Kato T; Yaku H; Morimoto T; Inuzuka Y; Tamaki Y; Yamamoto E; Yoshikawa Y; Kitai T; Taniguchi R; Iguchi M; Kato M; Takahashi M; Jinnai T; Kawai T; Komasa A; Nishikawa R; Kawase Y; Morinaga T; Su K; Kawato M; Seko Y; Inada T; Inoko M; Toyofuku M; Furukawa Y; Nakagawa Y; Ando K; Kadota K; Shizuta S; Ono K; Sato Y; Kuwahara K; Ozasa N; Kimura T
    J Card Fail; 2023 Aug; 29(8):1150-1162. PubMed ID: 36690136
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical and prognostic effects of atrial fibrillation in heart failure patients with reduced and preserved left ventricular ejection fraction.
    Linssen GC; Rienstra M; Jaarsma T; Voors AA; van Gelder IC; Hillege HL; van Veldhuisen DJ
    Eur J Heart Fail; 2011 Oct; 13(10):1111-20. PubMed ID: 21642293
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical and prognostic value of Duke's Activity Status Index along with plasma B-type natriuretic peptide levels in chronic heart failure secondary to ischemic or idiopathic dilated cardiomyopathy.
    Parissis JT; Nikolaou M; Birmpa D; Farmakis D; Paraskevaidis I; Bistola V; Katsoulas T; Filippatos G; Kremastinos DT
    Am J Cardiol; 2009 Jan; 103(1):73-5. PubMed ID: 19101233
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.